Search Results - "Mezzasoma, A.M"

Patients with primary antiphospholipid antibody syndrome and without associated vascular risk factors present a normal endothelial function by Gresele, P, Migliacci, R, Vedovati, M.C, Ruffatti, A, Becattini, C, Facco, M, Guglielmini, G, Boscaro, E, Mezzasoma, A.M, Momi, S, Pengo, V

“…Abstract Introduction Primary antiphospholipid antibody syndrome (PAPS) is characterized by venous or arterial thrombosis and positive antiphospholipid…”
Get full text

High-on-treatment platelet reactivity predicts adverse outcome after carotid artery stenting: A prospective study by Simonte, G., Guglielmini, G., Falcinelli, E., Isernia, G., Mezzasoma, A.M., Gresele, P., Lenti, M.

“…High-on-treatment platelet reactivity (HTPR) has been established as a predictor of major adverse cardiovascular events (MACE) in patients undergoing…”
Get full text

NCX4016: a novel antithrombotic agent by Gresele, P, Momi, S, Mezzasoma, A.M

“…Despite great advantages in antithrombotic treatments, important limitations of the presently available drugs encourage the search of more effective agents…”
Get full text

Inhibition of PAF synthesis by stimulated human polymorphonuclear leucocytes with cloricromene, an inhibitor of phospholipase A 2 activation by Ribaldi, E., Mezzasoma, A.M., Francescangeli, E., Prosdocimi, M., Nenci, G.G., Goracci, G., Gresele, P.

“…A phospholipase A 2 (PLA 2 ) represents the key enzyme in the remodelling pathway of platelet‐activating factor (PAF) synthesis in human polymorphonuclear…”
Get full text

Inhibition of PAF synthesis by stimulated human polymorphonuclear leucocytes with cloricromene, an inhibitor of phospholipase A2 activation by Ribaldi, E., Mezzasoma, A.M., Francescangeli, E., Prosdocimi, M., Nenci, G.G., Goracci, G., Gresele, P.

“…1 A phospholipase A2 (PLA2) represents the key enzyme in the remodelling pathway of platelet‐activating factor (PAF) synthesis in human polymorphonuclear (PMN)…”
Get full text